The outcome of the treatment was assessed based on Kyn/Trp baseline value in melanoma patients, a method used to quantify Trp and Kyn in plasma/serum where increased baseline value represents enhanced IDO activity and is usually associated with advanced disease stages. This evidence concerns the gene IDO1 and melanoma.